Thomas A. Raffin

Thomas A. Raffin is a declared insider at 2 companies (board member); the most frequent names are Lumos Pharma, Inc. and Akoya Biosciences, Inc. Between 20 May 2021 and 8 July 2025, the trades on record add up to 5 filings.

Every open-market trade on record is a purchase: 2 purchases worth €103k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 1 share grant.

Most recently, on 10 July 2025, the filings show a transaction in Akoya Biosciences, Inc. The last insider purchase was made public on 12 June 2023, 1,224 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.